Dermatology News

Dupilumab treatment was associated with the reduced risk for atopic march progression in pediatric and adolescent patients with atopic dermatitis, according to a study.

Vtama cream 1% has been approved in Japan for the treatment of adults with psoriasis as well as patients aged 12 years and older with atopic dermatitis, Dermavant Sciences announced in a press release.

Fixed-dose clindamycin phosphate 1.2%, adapalene 0.15% and benzoyl peroxide 3.1% gel demonstrated safety and efficacy across all age groups for the treatment of acne, according to a post hoc analysis.

We checked in with CDC Director Mandy K. Cohen, MD, MPH, for an update on the agency’s efforts to modernize the nation’s disease surveillance and data systems and improve how the CDC communicates with the public and physicians.

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.

Roflumilast cream 0.15% demonstrated long-term efficacy and tolerability in adults and children aged 6 years and older with atopic dermatitis, Arcutis announced in a press release.

Topical tapinarof cream showed significant improvement of moderate to severe atopic dermatitis while being well tolerated by adults and children down to age 2 years, according to two phase 3 clinical trials.

An 8-year-old girl was seen for right-sided neck pain and an underlying lymph node measuring 2.5 cm with surrounding inflammatory swelling. What's your diagnosis?

Isotretinoin is associated with a clinically marginal increased risk for severe adverse events, leading researchers to advise routine blood testing commence shortly after initiation, according to a study.

The NIH has awarded Emma Guttman-Yassky, MD, PhD, a $6.6 million grant to investigate dupilumab as a treatment for children with alopecia areata, Mount Sinai announced in a press release.